State of South San Francisco, CA Funding 2026

13 active investors and 8 funded companies in South San Francisco, CA. Most active: Founders Fund, Irving Investors, Lowercase Capital.

South San Francisco, CA accounts for 84 tracked companies with verified cap-table data, 84 of which disclose round sizes totalling $18B. The median disclosed raise is $105M, and the largest is Vaxcyte at $2.4B, ahead of Freenome ($1.1B) and Verily ($1B).

The names that recur most often on these south san francisco, ca cap tables are Alexandria Venture Investments (10 companies), Cormorant Asset Management (7 companies), Versant Ventures (7 companies), The Column Group (6 companies), Omega Funds (6 companies), Third Rock Ventures (6 companies). By latest disclosed round, the market skews Series A (28), Series B (17), Series C (12), IPO (7).

Best funded South San Francisco, CA companies

  1. Vaxcyte — $2.4B (latest: IPO)
  2. Freenome — $1.1B (latest: Growth)
  3. Verily — $1B (latest: Growth)
  4. ORIC Pharmaceuticals — $900M (latest: IPO)
  5. Angion Biomedica — $900M (latest: IPO)
  6. Annexon Biosciences — $634M
  7. Alumis — $529M (latest: Series C)
  8. Race — $500M (latest: Growth)
  9. Plenty — $500M (latest: Series D)
  10. Nkarta Therapeutics — $404M (latest: IPO)
  11. Glydways — $395M (latest: Series C)
  12. Denali Therapeutics — $349M (latest: Series A)
  13. Genesis Therapeutics — $300M (latest: Series B)
  14. NGM Bio Holdings — $257M (latest: Series A)
  15. Pliant Therapeutics — $251M (latest: IPO)

More South San Francisco CA research (1)

Research on comparable markets (18)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library